A Phase 1 interventional study of Abemaciclib in Hepatic Insufficiency, sponsored by Eli Lilly and Company. Completed at 5 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-05.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hepatic Insufficiency by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Hepatic Insufficiency · Eli Lilly and Company.
Among the 12 studies in Hepatic Insufficiency by Eli Lilly and Company, this one is the 5th largest by enrollment, is the only one that started in 2015, is one of 12 in phase 1, and was the 4th registered.
113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.
Browse Hepatic Insufficiency studies →2 of the 12 studies in Hepatic Insufficiency by Eli Lilly and Company are open now, in 4 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Hungary
Ages 18–85 · Healthy volunteers
Eli Lilly and Company · Sites in Hungary, New Zealand, Slovakia
Ages 18–85 · Healthy volunteers
By country, each count listing its studies:
Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is above the median of 29 across 100 interventional studies indexed under Hepatic Insufficiency.
Median enrollment 34 across the 12 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
2 of the studies in Hepatic Insufficiency by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07165002Eli Lilly and CompanyA Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment | 2026-11 |
| NCT07401862Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Hepatic Insufficiency by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study involves a single dose of a study drug called abemaciclib taken by mouth. The purpose of this study will be to measure how much study drug gets into the blood stream and how long the body takes to get rid of it when given to participants with mild, moderate, or severe liver impairment compared to healthy participants. In addition, the tolerability of the study drug will be evaluated.
This study will last approximately 3 weeks for each participant, including check-in and follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of Abemaciclib administered orally on Day 1 to participants with normal hepatic function.
Drug: Abemaciclib
Single dose of Abemaciclib administered orally on Day 1 to participants with mild hepatic impairment.
Drug: Abemaciclib
Single dose of Abemaciclib administered orally on Day 1 to participants with moderate hepatic impairment.
Drug: Abemaciclib
Single dose of Abemaciclib administered orally on Day 1 to participants with severe hepatic impairment.
Drug: Abemaciclib
Administered Orally
Also known as: LY2835219
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Abemaciclib and Active Metabolites
Time frame: Day 1: Predose, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity(AUC[0-inf]) of Abemaciclib and Active Metabolites
Time frame: Day 1: Predose, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose
| Milestone | Abemaciclib: Normal Hepatic Function | Abemaciclib: Mild Hepatic Impairment | Abemaciclib: Moderate Hepatic Impairment | Abemaciclib: Severe Hepatic Impairment |
|---|---|---|---|---|
| Started | 10 | 9 | 10 | 6 |
| Received abemaciclib | 10 | 9 | 10 | 6 |
| Completed | 10 | 9 | 10 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
| nanograms per milliliter (ng/mL) | Abemaciclib: Normal Hepatic Function | Abemaciclib: Mild Hepatic Impairment | Abemaciclib: Moderate Hepatic Impairment | Abemaciclib: Severe Hepatic Impairment |
|---|---|---|---|---|
| Abemaciclib | 133 ± 63 | 109 ± 65 | 83.9 ± 47 | 156 ± 44 |
| LSN2839567 | 31.2 ± 57 | 26.0 ± 31 | 13.6 ± 71 | 17.4 ± 45 |
| LSN3106729 | 10.4 ± 47 | 6.24 ± 27 | 4.96 ± 90 | 2.70 ± 41 |
| LSN3106726 | 55.3 ± 40 | 37.7 ± 35 | 19.2 ± 71 | 14.0 ± 27 |
| nanograms*hours/milliliter (ng*h/mL) | Abemaciclib: Normal Hepatic Function | Abemaciclib: Mild Hepatic Impairment | Abemaciclib: Moderate Hepatic Impairment | Abemaciclib: Severe Hepatic Impairment |
|---|---|---|---|---|
| Abemaciclib | 4460 ± 61 | 4280 ± 58 | 4940 ± 51 | 9310 ± 49 |
| LSN2839567 | 1420 ± 40 | 1090 ± 34 | 921 ± 46 | 846 ± 33 |
| LSN3106729 | 480 ± 55 | 257 ± 42 | 211 ± 251 | 35.3 ± NA |
| LSN3106726 | 3120 ± 40 | 2200 ± 39 | 1570 ± 57 | 1170 ± 30 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abemaciclib: Normal Hepatic Function | — | 0/10 (0%) | 4/10 (40%) |
| Abemaciclib: Mild Hepatic Impairment | — | 0/9 (0%) | 6/9 (66.7%) |
| Abemaciclib: Moderate Hepatic Impairment | — | 1/10 (10%) | 7/10 (70%) |
| Abemaciclib: Severe Hepatic Impairment | — | 0/6 (0%) | 3/6 (50%) |
| Event | Abemaciclib: Normal Hepatic Function | Abemaciclib: Mild Hepatic Impairment | Abemaciclib: Moderate Hepatic Impairment | Abemaciclib: Severe Hepatic Impairment |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/10 | 0/9 | 1/10 | 0/6 |
| Event | Abemaciclib: Normal Hepatic Function | Abemaciclib: Mild Hepatic Impairment | Abemaciclib: Moderate Hepatic Impairment | Abemaciclib: Severe Hepatic Impairment |
|---|---|---|---|---|
| HeadacheNervous system disorders | 3/10 | 2/9 | 1/10 | 0/6 |
| Catheter site erythemaGeneral disorders | 0/10 | 2/9 | 0/10 | 0/6 |
| DysgeusiaNervous system disorders | 0/10 | 2/9 | 0/10 | 0/6 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/10 | 2/9 | 0/10 | 0/6 |
| FatigueGeneral disorders | 0/10 | 0/9 | 2/10 | 0/6 |
| NauseaGastrointestinal disorders | 0/10 | 0/9 | 1/10 | 1/6 |
| Salivary hypersecretionGastrointestinal disorders | 0/10 | 0/9 | 0/10 | 1/6 |
| Catheter site painGeneral disorders | 0/10 | 1/9 | 0/10 | 1/6 |
| LacerationInjury, poisoning and procedural complications | 0/10 | 0/9 | 0/10 | 1/6 |
| Abdominal distensionGastrointestinal disorders | 0/10 | 1/9 | 0/10 | 0/6 |
All participants who received abemaciclib.
| Age, Continuous(years) | Abemaciclib: Normal Hepatic Function | Abemaciclib: Mild Hepatic Impairment | Abemaciclib: Moderate Hepatic Impairment | Abemaciclib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| Mean | 55.0 ± 4.8 | 56.6 ± 4.4 | 58.8 ± 5.5 | 53.2 ± 6.2 | 56.2 ± 5.3 |
| Sex: Female, Male(Participants) | Abemaciclib: Normal Hepatic Function | Abemaciclib: Mild Hepatic Impairment | Abemaciclib: Moderate Hepatic Impairment | Abemaciclib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| Female | 5 | 3 | 3 | 2 | 13 |
| Male | 5 | 6 | 7 | 4 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Abemaciclib: Normal Hepatic Function | Abemaciclib: Mild Hepatic Impairment | Abemaciclib: Moderate Hepatic Impairment | Abemaciclib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 0 | 4 | 8 |
| Not Hispanic or Latino | 8 | 7 | 10 | 2 | 27 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Abemaciclib: Normal Hepatic Function | Abemaciclib: Mild Hepatic Impairment | Abemaciclib: Moderate Hepatic Impairment | Abemaciclib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 3 | 0 | 7 |
| White | 7 | 7 | 7 | 4 | 25 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Abemaciclib: Normal Hepatic Function | Abemaciclib: Mild Hepatic Impairment | Abemaciclib: Moderate Hepatic Impairment | Abemaciclib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| United States | 10 | 9 | 10 | 6 | 35 |
The record gives a start of Mar 2015, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2019, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib